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SUMMARY The value of topical administration of antimicrobial agents to prevent irradi- 
ation mucositis of the oral cavity and oropharynx was investigated in this pilot study. 
Thirty-six patients receiving radiotherapy for head and neck cancer were included. Loz- 
enges containing polymyxin E, tobramycin, and amphotericin B (PTA-lozenges) were 
administered during and after the course of irradiation to eradicate gram-negative bacilli 
and yeasts. Mucosal reactions and dysphagia were assessed and oropharyngeal cultures 
were obtained. Thirty-six patients treated in a previous period served as controls. Sixteen 
of the 36 patients in each group received irradiation predominantly to the oral mucosa. 
Confluent mucositis was observed in only 1 of 16 patients receiving PTA-lozenges but in 
10 of the 16 patients of the control group (P = 0,001). Average duration of mucositis was 
also less with PTA-lozenges as well as dysphagia. Mucosal reactions and dysphagia in the 
patients who had mainly oropharyngeal mucosa in the treatment volume were not reduced. 
Persistent colonization by gram-negative bacilli occurred in only three patients. It is 
concluded that topical administration of polymyxin E, tobramycin, and amphotericin B may 
reduce irradiation mucositis of the oral cavity. The underlying mechanism must be further 
elucidated. Radiat Oncol Invest 1995;2:283-290. o 1995 Wdey-Liss, hc. 
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INTRODUCTION 
Irradiation mucositis is the most worrisome acute 
side effect of radiotherapy (RT) in the head and 
neck area and limits the rate at which fractionated 
irradiation can be delivered. It can cause severe 
discomfort to the patient with consequential weight 
loss, risk of dehydration, and loss of general physi- 
cal and psychological well-being. In addition, se- 
vere mucositis may impose unplanned and undes- 
ired treatment interruption. Accelerated and 
hyperfractionated radiation schedules result in in- 
creased acute mucosal reactions which often be- 
come dose limiting. Therefore, strategies to prevent 
or ameliorate radiation mucositis must be devel- 
oped to allow further intensification of RT for head 
and neck carcinomas and to reduce discomfort to 
the patient. 
Irradiation mucositis is basically the result of 
cell depletion caused by mitotic-linked cell death in 
the proliferating compartments of the epithelium. 
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Consequent shortage of functional cells results in 
impaired tissue function accompanied by inflam- 
matory changes. This inflammatory response to ra- 
diation damage may well be aggravated by second- 
ary factors such as infectious processes. 
Oral and oropharyngeal carriage of gram-neg- 
ative bacilli is low in healthy individuals, varying 
from 3% to 18% in different studies [ 1 4 .  In- 
creased carriage has been reported in several groups 
of compromised patients, including patients with 
malignant disease [1,3,5]. During and after radia- 
tion for head and neck cancer gram-negative bacilli 
were more frequently isolated from the oral cavity 
and oropharynx than prior to treatment [6-81. Eight 
of 14 patients who had undergone surgery for a 
tumor in the head and neck area were found to be 
persistently colonized with Enterobacteriaceae, 
Pseudomonadaceae or Acinetobacter species [4]. 
Spijkervet et al. [9] proposed that these gram-nega- 
tive bacilli may enhance the mucosal radiation reac- 
tion, possibly through the production of endotoxins 
which are mediators of inflammation. They re- 
ported promising results in the prevention of irradi- 
ation mucositis through selective elimination of 
oral flora [9]. In patients who used lozenges con- 
taining 2 mg polymyxin E, 1.8 mg tobramycin, and 
10 mg amphotericin B (PTA-lozenges) 4 times 
daily from the onset of a conventional irradiation 
course, eradication of the gram-negative bacilli was 
achieved after 3 weeks. Mucositis was significantly 
reduced in these patients when compared with pa- 
tients who received chlorhexidine rinsing or pla- 
cebo rinsing in an earlier study. 
In a prospective, non-randomized pilot study, 
we administered these FTA-lozenges to patients re- 
ceiving RT to the oral cavity and oropharynx. The 
aim was to expand the experience with selective 
elimination of oral flora to prevent irradiation mu- 
cositis and to determine whether it deserves testing 
on a larger scale. The results of this pilot study are 
presented here. 
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MATERIALS AND METHODS 
Patients 
From July 1991 till August 1992 36 consecutive 
patients were entered in the study after they had 
given informed consent (experimental group). All 
patients received external beam RT for head and 
neck cancer either as primary or as postoperative 
treatment. Only patients who received a total dose 
of 64 Gy or more to at least 50% of the mucosal 
surface of the oral cavity or oropharynx were in- 
cluded. Thirty -six patients treated between January 
1989 and July 1991 served as historical controls 
(control group). The institute’s patient registration 
system was used to retrieve a control patient match- 
ing each individual patient of the experimental 
group with regard to tumor site, intention of treat- 
ment (primary or postoperative RT), and total dose 
delivered. The simulation film of this patient was 
then reviewed to ascertain whether, as in the pa- 
tients of the experimental group, at least 50% of the 
mucosal surface of the oral cavity or oropharynx 
was irradiated to the full dose. The patient data of 
the registration system were searched starting at 
date July 1991 and went back in time until matching 
controls were found for all patients of the experi- 
mental group. Obviously, once a patient was se- 
lected as a control he or she could not be selected a 
second time. The age of the patients ranged from 40 
to 85 years (median 61 years, mean 61 years) in the 
experimental group and from 36 to 78 years (me- 
dian 61 years, mean 59 years) in the control group. 
Tumor sites, histology, TNM stage, radiation dose, 
and dental status are shown in Table 1. 
Radiotherapy 
Patients with oral cavity tumors were mostly oper- 
ated and received postoperative RT, whereas pa- 
tients with oropharyngeal tumors were generally 
treated by primary radiation. Almost all patients 
were treated with opposed lateral photon beams (4 
and 6 MV) to the primary tumor site and upper neck 
nodes. The boost dose was delivered through re- 
duced lateral and sometimes oblique opposed por- 
tals. The mid and lower neck nodes were treated 
through an anterior appositional photon field. In 
some cases a posterior field was added to supple- 
ment the dose in the posterior midcervical chain. 
Appositional electron beams of appropriate energy 
were used to boost nodal areas not included in the 
boost fields for the primary. Two patients with na- 
sal cavity tumors were treated with three-field ar- 
rangements. The two patients with tumors of the 
cheek received treatment to the ipsilateral side only 
by appositional lateral fields using a combination of 
electrons and photons. Treatment was given once- 
a-day, 5 timedweek, and in fractions of 2 Gy. 
Overall treatment time was 6.5-7 weeks and none 
of the patients had interruption of the treatment of 
more than 1 day. When RT was given as primary 
treatment, uninvolved nodal areas were treated to a 
dose of 44  Gy after which the primary tumor and 
neck metastases were boosted to a total dose of 
68-70 Gy. In the postoperative situation the entire 
surgical bed was treated to 50 Gy followed by a 
boost of 1 4 2 0  Gy to areas at high risk for recur- 
rence. Dose specification was according to Report 
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Table 1. Characteristics of Patients, Tumors, and Treatment for Control Group and 
Experimental Group, Separated by Mucosal Area Being Irradiated 
No. of patients 
mucosa irradiated mucosa irradiated 
Control Experimental Control Experimental 
group group group group 
350% of oral cavity 350% of oropharyngeal 
Total 16 16 20 20 
Site of tumor 
- - Oral cavity 15 15 
Nasal cavity 1 1 
- 15 15 Oropharynx - 
5 5 Nasopharynx - - 
Stage I - - - 
Stage I1 5 1 
Stage 111 4 3 8 7 
Other histologies 2 2 1 2 
Ly mphoepithelioma - - 
Adenoid cystic carcinoma - - 
Mucoepidermoid carcinoma 1 
Carcinoma, undifferentiated - - - 
Rhabdomyosarcoma - - - 
Anaplastic small cell carcinoma - 
Melanoma 1 
Definitive 
- - 
TNM stage (squamous cell carcinomas, UICC 1992) 
2 
3 
Stage IV 5 8 I 1  8 
- 
Histology 
Squamous cell carcinoma 14 14 18 18 
- 1 
1 - 
1 
1 
- - 
1 
1 - - 
- - - 
RT 
1 1 
70 Gy 2 2 17 17 
12 12 1 1 
1 1 
68 Gy - - 
64 GY 
68 Gy 
70 Gy 2 2 
Postoperative 
- - 
- - 
Dental status 
Dentulous 9 6 8 8 
Edentulous 7 10 12 12 
29 of the International Commission on Radiation 
Units and Measurements (ICRU) [ 101. 
Mucositis and Dysphagia Scoring 
Weekly assessment of acute reactions started in the 
first week of treatment and continued until they had 
completely subsided, but at least until 2 weeks after 
completion of the course of radiation. Mucosal re- 
actions and dysphagia were scored by two radio- 
therapists on a five-point scale (Table 2). In case of 
disagreement between the two observers, the high- 
est score was used in the analysis. Acute mucositis 
was graded according to the system that was intro- 
duced by Fletcher et al. [ 111: two grades of redness, 
studded fibrinous exudate, and confluent exudate. 
Since 1987 this scoring system has been applied 
routinely to all patients receiving RT to the head 
and neck area in our institute. 
Table 2. 
and Dysphagia 
Scores for Mucosal Reactions 
Acute reactions score 
Mucosa Normal 0 
Slight redness 1 
Severe redness 2 
Spotted mucositis 3 
Confluent mucositis 4 
Dysphagia No complaints 0 
Complaints, no medication 1 
Liquid feeding 3 
Tube feeding 4 
Medication needed 2 
Microbiological Techniques 
Assessment of oral and oropharyngeal flora was 
done once before the start of RT and before admin- 
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istration of PTA-lozenges. This was repeated 
weekly during the course of radiation and until 2 
weeks thereafter. Oral and oropharyngeal cultures 
were obtained by oral washing with isotonic saline. 
Each rinse was centrifuged, the supernatant dis- 
carded, and the pellet resuspended, which was then 
inoculated semiquantitatively on non-selective 
sheep blood agar (Mast Diagnostics Ltd., Morsey- 
side, UK), Sabouraud agar (BBL: Becton Dickin- 
son Microbiology Systems, Cockeysville, MD) for 
yeasts, mannitol-salt agar (Oxoid, Basingstroke, 
Hampshire, UK) for staphylococci, and eosin me- 
thylene blue agar (BBL) for aerobic and facultative 
anaerobic gram-negative bacilli. The Sabouraud 
agar plates were incubated for 96 hr at 29°C aerobi- 
cally. The other plates were incubated for 48 hr at 
37°C in 10% carbon dioxide. Enterobacteriaceae 
were identified by the Analytical Profile Index (API 
20E system, bioMCrieux S.A. ,  Marcy l’etoile, 
France). The detection level for gram-negative ba- 
cilli was lo2 colony forming units/m~. Patients were 
considered to be carriers of a particular microorgan- 
ism when a minimum of two consecutive rinses 
were positive for that microorganism. No cultures 
were obtained from patients in the historical control 
group. 
Oral Hygiene 
All patients received the same treatment and in- 
struction on oral hygiene including: 
Oral and dental examination by the oral surgeon, 
dentist, and oral hygienist. Dental treatment to 
eliminate foci of infection or mechanical irritation 
was performed. 
Weekly cleansing of the oral cavity, instruction to 
maintain oral hygiene, and brush training by the 
oral hygienist. 
Rinsing of the oral cavity and oropharynx with 
salt-soda solution 6-8 times daily. 
Daily application of neutral 1% sodium fluoride 
gel with custom-made carriers in dentate patients. 
Edentulous patients were not allowed to wear 
their prostheses during the course of irradiation. 
PTA-Lozenges 
Lozenges containing 2 mg polymyxin E, 1.8 mg 
tobramycin, and 10 mg amphotericin B were taken 
4 times daily by patients of the experimental group. 
Administration started 2 days before initiation of 
RT and was continued until 2 weeks after comple- 
tion of RT. 
statistics 
Fisher’s exact probability test was used to test the 
significance of differences in mucosa and dyspha- 
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gia scores as well as numbers of positive cultures 
between treatment groups. Average durations of 
mucosal reactions and dysphagia were compared by 
the t-test. 
RESULTS 
Mucositis 
Sixteen of the 36 patients of both the experimental 
group and the control group received irradiation 
predominantly to the oral mucosa. The remaining 
20 patients of both groups had mainly oropharyn- 
geal mucosa in the treatment volume. Irradiation of 
the oral mucosa produced confluent mucositis in 
only 1 of the 16 patients receiving PTA-lozenges 
but in 10 of 16 patients of the control group 
(P = 0.001, Fisher’s exact test). Seven of 16 pa- 
tients of the experimental group vs. all patients of 
the control group developed spotted mucositis 
(P < 0.001, Fisher’s exact test). If spotted or con- 
fluent mucositis occurred, the average duration was 
21 days (standard deviation 16 days) in the experi- 
mental group and 36 days (standard deviation 16 
days) in the control group (P = 0.04, t-test). On 
average, the first signs of fibrinous exudate were 
observed 8 days later in the experimental group 
compared to the control group. Figure 1 shows the 
scores for mucosal reactions of the oral cavity in the 
control group (Fig. 1A) and the experimental group 
(Fig. 1B). Seventy-eight percent (31140) of patients 
irradiated predominantly to the oropharyngeal mu- 
cosa developed confluent mucositis with no signifi- 
cant difference between the experimental and con- 
trol groups. Severity of mucositis was comparable 
in dentulous and edentulous patients. 
Dysphagia 
Dysphagia scores show a similar pattern for the 
various groups and subgroups although differences 
are not as evident as for mucosal reactions (Fig. 2). 
Although not statistically significant, PTA-loz- 
enges did seem to reduce the severity of dysphagia 
produced by irradiation of the oral mucosa. Only 
half (8/16) of the patients of the experimental group 
vs. 13 of 16 patients of the control group needed 
analgetics (P = 0.14, Fisher’s exact test). Eighty- 
five percent (34140) of patients irradiated predomi- 
nantly to the oropharynx required analgetics with 
no significant difference between the experimental 
and control groups. 
Oral and Oropharyngeal Flora 
Before the start of RT gram-negative bacilli were 
isolated from rinses of 6 patients (17%). Eleven 
patients in whom initial rinses showed no growth 
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Fig. 1. 
the oral cavity. a: Control group. b: Experimental group. 
Scores for mucosal reactions during and after RT of patients irradiated predominantly to 
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Fig. 2. 
cavity. a: Control group. b: Experimental group. 
Scores for dysphagia during and after RT of patients irradiated predominantly to the oral 
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Seventy-eight percent of patients irradiated 
predominantly to the oropharyngeal mucosa devel- 
oped confluent mucositis. This corresponds to what 
generally can be expected when this region is irradi- 
ated with a conventional fractionation schedule to a 
total dose of 68-70 Gy [15]. There was no differ- 
ence between the experimental group and the con- 
trol group. When radiation was directed mainly to 
the oral cavity severity of mucositis was signifi- 
cantly less in patients receiving PTA-lozenges 
when compared to the control group. Also dyspha- 
gia was less although this difference was not statis- 
tically significant. These patients differed in two 
major aspects from those who received irradiation 
predominantly to the oropharynx. First, obviously 
the sites of tumor location and thus the regions that 
were treated differed. Second, 14 of the 16 patients 
irradiated to the oral cavity previously had surgery, 
whereas RT was the primary treatment for 18 of the 
20 patients who had the tumor located in or near the 
oropharynx. 
The remarkable mildness of mucosal reactions 
when PTA-lozenges were prophylactically admin- 
istered suggests that microorganisms and specifi- 
cally gram-negative bacilli can aggravate radiation 
mucositis in the oral cavity. This was postulated by 
Spijkervet et al. [9], who observed merely redness 
as the most severe sign of irradiation mucositis in 
15 head and neck cancer patients using PTA-loz- 
enges. In their study this was associated with suc- 
cessful elimination of oral gram-negative bacilli, 
i.e., significant reduction of carriage after 3 weeks 
of treatment. Twelve of the 15 patients received 
postoperative RT using a conventional schedule to 
total doses of 66-70 Gy. These patients are thus 
comparable to the subgroup from our study that 
seems to benefit from PTA-lozenges. Complete 
eradication of gram-negative bacilli was not 
achieved in our study but carriage occurred in only 
three patients. From the other patients gram-nega- 
tive bacilli were isolated incidentally. This may 
reflect temporary presence of these bacilli which 
can have been acquired from food or beverage 
[ 16,171 and which may be subsequently eliminated 
by the antibiotic treatment. Due to the technique of 
culturing, patients carrying low quantities of gram- 
negative bacilli may have been falsely identified as 
negative. Assuming that these low quantities are 
easier to eliminate, the effectiveness of the antibiot- 
ics with regard to prevention of carriage of these 
particular microorganisms may thus have been un- 
derestimated. The analysis is complicated by the 
fact that no cultures from the historical controls 
were available. 
Interestingly, the antimicrobial prophylaxis 
seemed effective only in the oral cavity. Whether 
had one or more positive rinses after the start of RT. 
In total, gram-negative bacilli could be isolated 
from 17 of the 36 patients at one or more occasions, 
from 9 of 16 patients who were irradiated mainly to 
the oral cavity, and from 8 of 20 who received 
treatment predominantly to the oropharynx. The 
frequency of isolation of gram-negative bacilli did 
not decrease until after the completion of RT. How- 
ever, of all patients only three had two or more 
consecutive rinses showing growth of the same spe- 
cies and could be considered carriers. Yeasts, 
mostly candida, were found in the rinses of 14 of 
the 36 patients (39%) at the onset of treatment. 
Eight of them also had subsequent positive rinses. 
Ten patients who were initially negative became 
positive during or after the course of radiation. 
Thus, a total of 24 patients had yeasts isolated from 
their mouth or throat: 13 of the 16 irradiated to the 
oral cavity and 1 1  of 20 irradiated to the orophar- 
ynx. There was a gradual decrease of the number of 
positive rinses during the treatment to 3/36 (8%) 
after completion of treatment. 
DISCUSSION 
Selective modulation of oral and oropharyngeal 
flora was attempted through topical application of 
polymyxin E, tobramycin, and amphotericin B. 
The combination of the two antibiotics has bacteri- 
cidal activity against most gram-negative species. 
They are non-absorbable and the mode of adminis- 
tration, i.e., lozenges, ensures sufficiently long 
contact time [9]. Amphotericin B is active against 
yeasts. 
The prevalence of gram-negative bacilli in oral 
and pharyngeal cultures from patients with ad- 
vanced cancer has been reported by Jobbins et al. 
[5] to be as high as 49%. Spijkervet [4] observed 
colonization in 57% of patients who had undergone 
surgery for a tumor in the head and neck area. In 
our study the prevalence of gram-negative bacilli 
prior to RT was 17%, which is low compared to 
what is reported by the other investigators. How- 
ever, our patients were not hospitalized and proba- 
bly had less advanced disease than those studied by 
Jobbins et al. [5]. Another potential factor contrib- 
uting to this difference may be the technique of 
culturing. Preincubation of samples in a selective 
broth gives a higher yield of gram-negative bacilli 
than direct plating as was done in our study [3,4]. 
This increase can be up to a factor of three [3]. At 
the onset of treatment yeasts, mostly candida, were 
isolated from 39% of our patients. This is in good 
agreement with observations by others [ 12-14]. 
With use of PTA-lozenges there was a gradual de- 
crease of positive patients to 8% after completion 
of RT. 
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this truly reflects a difference between anatomic 
sites is not clear. Other strains than the gram-nega- 
tives may have a role in the oropharynx or microor- 
ganisms in general may only minimally affect the 
radiation response of the oropharyngeal mucosa. 
Most of the patients who showed benefit from the 
antimicrobial prophylaxis, both in the study by 
Spijkervet et al. [9] and in our study, underwent 
surgery prior to radiation. This may have altered the 
colonization defense mechanisms through manipu- 
lations in the oral cavity or through less specific 
mechanisms. The latter is supported by the observa- 
tion that gram-negative carriage was enhanced in 
relatively young patients who had undergone ortho- 
pedic operations [ 11. 
It is concluded that this pilot study confirms 
the results of Spijkervet et al. [9]. Topical adminis- 
tration of polymyxin E, tobramycin, and ampho- 
tericin B may prevent severe irradiation mucositis 
of the oral cavity. Further testing in a randomized, 
placebo-controlled study is warranted. The role of 
microorganisms in the pathogenesis of irradiation 
mucositis must be further elucidated. 
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